|1.||Yang, Qian: 2 articles (01/2015 - 06/2014)|
|2.||Gao, Li: 2 articles (01/2015 - 06/2014)|
|3.||Machado, Ubiratan Fabres: 2 articles (09/2014 - 01/2009)|
|4.||Mao, Zixu: 2 articles (06/2014 - 10/2009)|
|5.||Cowan, Christopher W: 2 articles (12/2012 - 07/2005)|
|6.||Mo, Xiaokui: 1 article (12/2015)|
|7.||Marcucci, Guido: 1 article (12/2015)|
|8.||Chen, Ching-Shih: 1 article (12/2015)|
|9.||Wang, Zhen-Hua: 1 article (12/2015)|
|10.||Miao, Yin-Sha: 1 article (12/2015)|
|1.||Cardiomegaly (Heart Hypertrophy)
01/01/2004 - "Balancing contractility and energy production: the role of myocyte enhancer factor 2 (MEF2) in cardiac hypertrophy."
06/08/2012 - "Myocyte enhancer factor 2 (MEF2) transcription factors drive the genetic reprogramming that precipitates pathological cardiac hypertrophy and remodeling. "
01/01/2011 - "In contrast, class IIa HDACs have been shown to repress cardiac hypertrophy by inhibiting cardiac-specific transcription factors such as myocyte enhancer factor 2 (MEF2), GATA4, and NFAT in the heart. "
05/01/2010 - "The calcineurin-myocyte enhancer factor 2c pathway mediates cardiac hypertrophy induced by endoplasmic reticulum stress in neonatal rat cardiomyocytes."
04/01/2010 - "Here, we found that myocyte enhancer factor 2C (MEF2C) and histone deacetylase 5 (HDAC5), two key regulators of cardiac hypertrophy, are targets of polycystin-dependent fluid stress sensing in renal epithelial cells in mice. "
|2.||Coronary Artery Disease (Coronary Atherosclerosis)
03/01/2012 - "Recent studies showed that the 21-base pair deletion mutation (Δ21) in myocyte enhancer factor 2A (MEF2A) gene could be an inherited marker for coronary artery disease. "
01/01/2015 - "Association of variants in the myocyte enhancer factor 2A (MEF2A) gene and the risk of coronary artery disease (CAD) has drawn much attention but remains controversial. "
01/01/2014 - "We investigated mutations and polymorphisms of the coronary artery disease (CAD)-related myocyte enhancer factor 2A (MEF2A) gene in a Chinese population. "
04/01/2013 - "To assess the relationship between mutations of the myocyte enhancer factor 2A (MEF2A) and premature coronary artery disease (PCAD) in a Chinese population. "
08/01/2010 - "A mutation in MEF2A (myocyte enhancer factor-2A) had been reported to be the first gene linked directly to coronary artery disease (CAD). "
05/01/2005 - "These studies identify a new mechanism, the myocyte enhancer factor 2 (MEF2) signaling pathway of vascular endothelium, for the pathogenesis of CAD, and also confirm the role of inflammation in the disease process."
07/09/2004 - "Myocyte enhancer factor 2 mediates vascular inflammation via the p38-dependent pathway."
01/01/2005 - "Also, it has been established that myocyte enhancer factor 2A (MEF2A) plays a vital role in the development of cardiovascular problems like atherosclerosis and restenosis after angioplasty inflammation. "
01/01/2015 - "Transcription factor myocyte enhancer factor 2D regulates interleukin-10 production in microglia to protect neuronal cells from inflammation-induced death."
02/05/2010 - "Unlike conditional deletion of LAP2alpha in late embryonic striated muscle, its complete knockout caused systolic dysfunction in young mice, accompanied by sporadic fibrosis in old animals, as well as deregulation of major cardiac transcription factors GATA4 and myocyte enhancer factor 2c. "
01/01/2010 - "The present study was designed to determine whether atorvastatin reduced hypertension-induced cardiac remodeling and whether these effects involved Protein Kinase D (PKD) and Myocyte Enhancer Factor 2D (MEF2D), factors known to be implicated in cardiac hypertrophy and fibrosis. "
01/01/2009 - "The present study was designed to investigate the role of contractile activity per se in the regulation of SLC2A4 gene expression as well as in the participation of the transcriptional factors myocyte enhancer factor 2D (MEF2D), hypoxia inducible factor 1a (HIF-1a), and thyroid hormone receptor-alpha (TRalpha). "
09/26/2014 - "Rat soleus muscles were incubated during 180 min with insulin, added or not with wortmannin (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (PI3K)-inhibitor), ML9 (serine/threonine protein kinase (AKT) inhibitor) and tumor necrosis factor (TNF, GLUT4 repressor), and processed for analysis of GLUT4 protein (Western blotting); Slc2a4, myocyte enhancer factor 2a/d (Mef2a/d), hypoxia inducible factor 1a (Hif1a), myogenic differentiation 1 (Myod1) and nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (Nfkb1) messenger ribonucleic acids (mRNAs) (polymerase chain reaction (PCR)); and AT-rich- (myocyte-specific enhancer factor 2 (MEF2)-binding site), E-box- (hypoxia inducible factor 1 alpha (HIF1A)- and myoblast determination protein 1 (MYOD1)-binding site), and NFKB-binding activity (electrophoretic mobility assay). "
|2.||Thyroid Hormone Receptors (Thyroid Hormone Receptor)
|3.||protein kinase D
|5.||Transcription Factors (Transcription Factor)
|6.||Protein Kinases (Protein Kinase)
|7.||Proteins (Proteins, Gene)
|9.||Histone Deacetylases (Histone Deacetylase)
|1.||Angioplasty (Angioplasty, Transluminal)